Jasper Therapeutics (NASDAQ:JSPR) and NutraLife Biosciences (OTCMKTS:NLBS) Head to Head Comparison

NutraLife Biosciences (OTCMKTS:NLBS) and Jasper Therapeutics (NASDAQ:JSPR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for NutraLife Biosciences and Jasper Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NutraLife Biosciences	0	0	0	0	0.00
Jasper Therapeutics	1	5	6	0	2.42

Jasper Therapeutics has a consensus price target of $19.88, indicating a potential upside of 1,792.86%. Given Jasper Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than NutraLife Biosciences.

Profitability

This table compares NutraLife Biosciences and Jasper Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NutraLife Biosciences	N/A	N/A	N/A
Jasper Therapeutics	N/A	-372.18%	-153.67%

Earnings & Valuation

This table compares NutraLife Biosciences and Jasper Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NutraLife Biosciences	N/A	N/A	N/A	($0.02)	N/A
Jasper Therapeutics	N/A	N/A	-$75.80 million	($4.60)	-0.23

Jasper Therapeutics is trading at a lower price-to-earnings ratio than NutraLife Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.8% of Jasper Therapeutics shares are owned by institutional investors. 34.6% of NutraLife Biosciences shares are owned by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

About NutraLife Biosciences

NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, dietary, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil derived from industrial hemp; tinctures; topical lotions and oils applied directly to the skin to treat pain or inflammation; face creams; massage oils; nutraceutical sprays with CBD as an added ingredient; and pet products. The company also offers other products, such as skincare and sanitizer products. NutraLife BioSciences, Inc. sells its products through nutralifebiosciences.com, as well as through private label distributors, online retailers, and retail outlets. The company was formerly known as NutraFuels, Inc. and changed its name to NutraLife BioSciences, Inc. in March 2019. NutraLife BioSciences, Inc. was incorporated in 2010 and is based in Coconut Creek, Florida.

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.